These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35743522)

  • 1. The Latest Data Specifically Focused on Long-Term Oncologic Prognostication for Very Old Adults with Acute Vulnerable Localized Prostate Cancer: A Nationwide Cohort Study.
    Wu SY; Effendi FF; Canales RE; Huang CC
    J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Clinical Outcomes of Radical Prostatectomy versus IMRT with Long-Term Hormone Therapy for Relatively Young Patients with High- to Very High-Risk Localized Prostate Cancer.
    Shih HJ; Chang SC; Hsu CH; Lin YC; Hung CH; Wu SY
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncologic Outcomes of Radical Prostatectomy and High-Dose Intensity-Modulated Radiotherapy with Androgen-Deprivation Therapy for Relatively Young Patients with Unfavorable Intermediate-Risk Prostate Adenocarcinoma.
    Wu SY; Chang SC; Chen CI; Huang CC
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33806181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Medical Resource Consumption of Radical Prostatectomy vs. Intensity-Modulated Radiotherapy for Old Patients With Prostate Cancer: A Nationwide Population-Based Cohort Study.
    Wu SY; Effendi FF; Peng JY; Huang CC
    Front Med (Lausanne); 2022; 9():843709. PubMed ID: 35592854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute, Subchronic, and Chronic Complications of Radical Prostatectomy Versus Radiotherapy With Hormone Therapy in Older Adults With High-Risk Prostate Adenocarcinoma.
    Wu SY; Huy LD; Liao CJ; Huang CC
    Front Oncol; 2022; 12():875036. PubMed ID: 35586485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
    Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
    Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis.
    Hayashi N; Osaka K; Muraoka K; Hasumi H; Makiyama K; Kondo K; Nakaigawa N; Yao M; Mukai Y; Sugiura M; Takano S; Ito E; Kaizu H; Koike I; Hata M; Taguri M; Miyoshi Y; Izumi K; Kawahara T; Uemura H
    World J Urol; 2020 Oct; 38(10):2477-2484. PubMed ID: 31875247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
    Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
    Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders.
    Liu JM; Liu YP; Chuang HC; Wu CT; Su YL; Hsu RJ
    PLoS One; 2020; 15(2):e0229263. PubMed ID: 32074125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
    Preisser F; Chun FKH; Pompe RS; Heinze A; Salomon G; Graefen M; Huland H; Tilki D
    Eur Urol; 2019 Jul; 76(1):106-114. PubMed ID: 30772034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensity-modulated radiotherapy versus radical prostatectomy in patients with localized prostate cancer: long-term follow-up.
    Merino T; San Francisco IF; Rojas PA; Bettoli P; Zúñiga A; Besa P
    BMC Cancer; 2013 Nov; 13():530. PubMed ID: 24209381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of treatments for high-risk prostate cancer patients.
    Jayadevappa R; Lee DI; Chhatre S; Guzzo TJ; Malkowicz SB
    Urol Oncol; 2019 Sep; 37(9):574.e11-574.e18. PubMed ID: 31285113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
    Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
    Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes for Young Men With Localized Intermediate-Risk Prostate Cancer: An Analysis of the NCDB.
    Chua S; Qureshi MM; Boyd G; Gignac GA; Hirsch AE
    Clin Genitourin Cancer; 2020 Oct; 18(5):e531-e542. PubMed ID: 32220567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes from dose-escalated image-guided intensity-modulated radiotherapy with androgen deprivation: encouraging results for intermediate- and high-risk prostate cancer.
    Wilcox SW; Aherne NJ; Benjamin LC; Wu B; de Campos Silva T; McLachlan CS; McKay MJ; Last AJ; Shakespeare TP
    Onco Targets Ther; 2014; 7():1519-23. PubMed ID: 25210465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer.
    Mizowaki T; Norihisa Y; Takayama K; Ikeda I; Inokuchi H; Nakamura K; Kamba T; Inoue T; Kamoto T; Ogawa O; Hiraoka M
    Int J Clin Oncol; 2016 Feb; 21(1):148-55. PubMed ID: 26141133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transitioning from conformal radiotherapy to intensity-modulated radiotherapy after radical prostatectomy: Clinical benefit, oncologic outcomes and incidence of gastrointestinal and urinary toxicities.
    Flores-Balcázar CH; Urías-Arce DM; Bourlon MT; Gabilondo-Navarro F; Pérez-Álvarez SI; Ramos-Prudencio R; Rodríguez-Covarrubias F
    Rep Pract Oncol Radiother; 2020; 25(4):568-573. PubMed ID: 32494230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer.
    Mitchell CR; Boorjian SA; Umbreit EC; Rangel LJ; Carlson RE; Karnes RJ
    BJU Int; 2012 Dec; 110(11):1709-13. PubMed ID: 22934913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer: A Systematic Review and Meta-analysis.
    Greenberger BA; Zaorsky NG; Den RB
    Eur Urol Focus; 2020 Mar; 6(2):404-418. PubMed ID: 31813810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.